Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)

NCT05515770 is registered in ClinicalTrials.gov with Evandro Chagas National Institute of Infectious Disease as lead sponsor.

NCT NCT05515770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05515770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)
Lead sponsor
Evandro Chagas National Institute of Infectious Disease
Phase
Phase 3
Overall status
Recruiting
Start date
September 20, 2022
Completion date
February 28, 2026
Enrollment
1,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections